Creative Biolabs Provides Aducanumab for Alzheimer’s Disease for Preclinical Study

October 25 19:16 2019

New York, US, October 25, 2019 Having engaged in the rapidly emerging therapeutic antibodies field for decades, Creative Biolabs has earned a favorable reputation by virtue of its fully functional products and professional services. Aducanumab from the company is prepared for academic or industrial clients to support with their research projects on Alzheimer’s Disease.


At present, there are 50 million people worldwide suffering from Alzheimer’s disease, a persistent neurological dysfunction with a slow onset and worsening over time, with explosive growth, which is expected to reach 150 million people by 2050. Since Alzheimer’s diseases are usually accompanied with memory loss and confusion, not only patients but also their families are all suffering from these symptoms.


In spite of over one hundred failed R&D projects on Alzheimer’s diseases in the last 20 years, recently, a favorable turn eventually has come up when Aducanumab has proved efficiently to slow disease progression. The transmembrane precursor protein encoded by APP are cleaved to form peptides that further form the protein basis of the amyloid plaques found in the brains of patients with Alzheimer disease. To better assist with the preclinical R&D of Alzheimer’s diseases, Creative Biolabs offers endotoxin free Anti-APP Therapeutic Antibodies (Aducanumab), which are ready to use in animal-based assays.


Aducanumab from Creative Biolabs is a recombinant human monoclonal antibody expressed in CHO binding to human amyloid beta (Abeta, Aβ), designed for the treatment of Alzheimer’s disease. It is IgG1 – kappa type, 145.9 kDa, suitable for use in Neut, ELISA, IF, IP, FuncS, FC, WB and most other immunological methods.


“With years of experience in therapeutic antibodies, we are confident to guarantee our clients endotoxin free products with high-affinity. Our Aducanumab is equipped with high specificity and low off-target activity, which is low or non immunogenic. We promise a long-term benefit with short-term therapy,” introduced by a senior scientist from Creative Biolabs.


Undoubtedly, although the progress has been made to slow disease progression, more efforts are required to develop a novel drug to cure Alzheimer’s disease. On the long journey to a complete curable drug to treat Alzheimer, Creative Biolabs is ready to serve numerous researchers with the highest quality products and services to accelerate the pace of technology evolvement.


More information on a wide range of antibodies can be reached at


About Creative Biolabs

Creative Biolabs was founded by scientists who are dedicated to the treatment of a wide variety of diseases, including immune disorders, cancers, infections and more. Over the last 10 years, Creative Biolabs has becoming a leader of recombinant antibody (rAb) discovery and manufacturing, providing high quality service to customers in academia and industry fields all over the world. The cutting-edge hybridoma development and phage display platforms allow the production of the most comprehensive list of recombinant antibody products and extensive service portfolio at the most competitive price.

Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-619-7922
Address:45-1 Ramsey Road
City: Shirley
State: New York
Country: United States